The National Cancer Medicines Advisory Group (NCMAG) Programme have approached Ovacome as they are currently considering trametinib for patients with recurrent or progressive low grade serous ovarian carcinoma after at least one line of platinum-based chemotherapy for off-label use in NHSScotland.
The aim of the NCMAG programme is to issue national advice on the clinical- and cost-effectiveness of off-label and off-patent uses of cancer medicines, and to improve outcomes for cancer patients across NHSScotland.
We have been invited to make a written submission as part of this process and it is really important that it includes the views and experiences of our members. We would like to use anonymous quotes from our community in our submission.
If you have been diagnosed with low grade serous ovarian cancer and you have been prescribed trametinib as part of your treatment, it would be great to hear from you. We would also love to hear experiences from friends, family members and carers. We have written a short survey which you can use to share your experiences. The link to the survey is here: surveymonkey.com/r/YDJQZR5
If this is something you would like to contribute to, we would be grateful if you could complete the survey by Monday 12th August 2024
If you would prefer to share your experience in another way such as by email or over the phone, please do let us know. You can contact the support team by calling 0800 008 7054 or by emailing support@ovacome.org.uk. Our support service is available Monday – Friday 10am – 5pm.
Please do get in touch if you have any questions or if we can help with any further information.
Best wishes
Cathryn - Ovacome Support
